Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

Housatonic1864 Mar. 16 at 4:32 PM

$TLSA if you take a look at $TLSA and it’s history before the big news, you’d see something is taking place that will be magnificent with the ticker. If you’re looking for a good growth opportunity, this is it. Sit back and ride the waves🏴‍☠️

0 · Reply

Housatonic1864 Mar. 16 at 3:44 PM

$TLSA I like it😂

0 · Reply

Housatonic1864 Mar. 16 at 2:29 PM

$TLSA PR please 🙏

0 · Reply

rp6577 Mar. 13 at 5:22 PM

$TLSA might have to add a bit more at these prices 🤔

1 · Reply

Housatonic1864 Mar. 13 at 2:26 PM

$TLSA we need a positive PR before the EPS report.

0 · Reply

Bstyle13 Mar. 13 at 3:33 AM

$TLSA

1 · Reply

Zenlama Mar. 11 at 2:53 PM

$TLSA https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-03-09-2026/card/biotech-stocks-rally-on-departure-of-polarizing-fda-official-MSjPZ3XhEXbEOrftphiC?mod=mhp

0 · Reply

Zenlama Mar. 11 at 2:47 PM

$TLSA Dr. Vinay Prasad, of the FDA, is finally out! So many biotechs have been stifled by him. I see a Renaissance in biotech about to begin. GLTA

1 · Reply

Gegau001 Mar. 10 at 2:42 PM

$TLSA Let's wait and buy more, it will be a huge hit...There are many irons in the fire, let's be patient...1.6 million shorts will contribute in turn.

1 · Reply

Airforcecaptain Mar. 9 at 7:05 PM

$TLSA I’m not sure if Harvard is fully confident with Foralumab as the only option. https://www.neurologylive.com/view/cd40l-inhibitor-frexalimab-enters-phase-3-frexite-trial-non-relapsing-secondary-progressive-multiple-sclerosis

1 · Reply

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

Jan 20, 2026, 11:15 AM EST - 7 weeks ago

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Jan 16, 2026, 2:45 PM EST - 2 months ago

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

Jan 16, 2026, 7:00 AM EST - 2 months ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Jan 9, 2026, 7:00 AM EST - 2 months ago

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

Dec 29, 2025, 8:00 AM EST - 2 months ago

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

Dec 19, 2025, 11:00 AM EST - 3 months ago

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Dec 17, 2025, 10:00 AM EST - 3 months ago

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

Dec 17, 2025, 8:45 AM EST - 3 months ago

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

Dec 15, 2025, 3:07 PM EST - 3 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Dec 15, 2025, 7:30 AM EST - 3 months ago

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

Dec 12, 2025, 2:10 PM EST - 3 months ago

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

Dec 2, 2025, 7:00 AM EST - 3 months ago

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

Nov 25, 2025, 8:30 AM EST - 3 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Nov 13, 2025, 8:30 AM EST - 4 months ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Oct 31, 2025, 9:43 AM EDT - 4 months ago

Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot

Oct 29, 2025, 7:00 AM EDT - 4 months ago

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Sep 30, 2025, 8:30 AM EDT - 5 months ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Sep 24, 2025, 8:30 AM EDT - 6 months ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Sep 15, 2025, 8:00 AM EDT - 6 months ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Sep 5, 2025, 8:30 AM EDT - 6 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Aug 14, 2025, 8:30 AM EDT - 7 months ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 7 months ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Jul 21, 2025, 7:00 AM EDT - 8 months ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 11:08 PM EDT - 9 months ago

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Jun 13, 2025, 10:30 AM EDT - 9 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 9 months ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 10 months ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 10 months ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 9, 2025, 7:00 AM EDT - 11 months ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 11 months ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 11 months ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 11, 2025, 9:15 AM EST - 1 year ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Jan 23, 2025, 3:00 PM EST - 1 year ago

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Jan 23, 2025, 8:54 AM EST - 1 year ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Jan 22, 2025, 4:05 PM EST - 1 year ago

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Jan 8, 2025, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Nov 1, 2024, 1:00 PM EDT - 1 year ago

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Oct 30, 2024, 10:29 PM EDT - 1 year ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Appoints New Chief Executive Officer

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Granted FDA Fast Track Designation

Housatonic1864 Mar. 16 at 4:32 PM

0 · Reply

Housatonic1864 Mar. 16 at 3:44 PM

$TLSA I like it😂

0 · Reply

Housatonic1864 Mar. 16 at 2:29 PM

$TLSA PR please 🙏

0 · Reply

rp6577 Mar. 13 at 5:22 PM

$TLSA might have to add a bit more at these prices 🤔

1 · Reply

Housatonic1864 Mar. 13 at 2:26 PM

$TLSA we need a positive PR before the EPS report.

0 · Reply

Bstyle13 Mar. 13 at 3:33 AM

$TLSA

1 · Reply

Zenlama Mar. 11 at 2:53 PM

$TLSA https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-03-09-2026/card/biotech-stocks-rally-on-departure-of-polarizing-fda-official-MSjPZ3XhEXbEOrftphiC?mod=mhp

0 · Reply

Zenlama Mar. 11 at 2:47 PM

$TLSA Dr. Vinay Prasad, of the FDA, is finally out! So many biotechs have been stifled by him. I see a Renaissance in biotech about to begin. GLTA

1 · Reply

Gegau001 Mar. 10 at 2:42 PM

$TLSA Let's wait and buy more, it will be a huge hit...There are many irons in the fire, let's be patient...1.6 million shorts will contribute in turn.

1 · Reply

Airforcecaptain Mar. 9 at 7:05 PM

1 · Reply

Bhanu82 Mar. 9 at 5:57 PM

$TLSA https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-03-09-2026/card/biotech-stocks-rally-on-departure-of-polarizing-fda-official-MSjPZ3XhEXbEOrftphiC?mod=mhp

0 · Reply

Housatonic1864 Mar. 9 at 12:42 AM

$TLSA https://www.tizianalifesciences.com/category/news/

0 · Reply

Housatonic1864 Mar. 4 at 7:17 PM

$TLSA need a PR about now🤔

1 · Reply

Housatonic1864 Mar. 2 at 7:20 PM

$TLSA $TSLA

1 · Reply

Housatonic1864 Mar. 2 at 7:18 PM

$TLSA after hours should be exciting 😂

0 · Reply

Housatonic1864 Mar. 2 at 3:18 PM

$TLSA push dang it😂

0 · Reply

rp6577 Feb. 27 at 7:54 AM

$TLSA I think this could get quite exciting over the next few months 👌

3 · Reply

BillionerOfKing Feb. 27 at 12:20 AM

$TLSA Current Stock Price: $1.46 Contracts to trade: $2.5 TLSA Mar 20 2026 Call Entry: $0.09 Exit: $0.18 ROI: 98% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Gegau001 Feb. 26 at 4:53 PM

$TLSA You can see that the active ingredient works wonders... I'm looking forward to the next results... The course has been downloaded, I couldn't care less about that.... The next milestone will cause a short squeeze and we'll be back on top!!!... gla

0 · Reply

Housatonic1864 Feb. 26 at 4:46 PM

$TLSA When? That is the question. All I need is a quarter 25 cents. I’ll make plenty 💥

0 · Reply

BioRich Feb. 26 at 3:29 PM

$TLSA $SCYX $NGEN Thanks to @DataJim for getting me focused on $SCYX. The timing was perfect as they've started dosing, which is an exciting milestone. I've not started a nice position in it. Already have a nice position in $TLSA and will review $NGEN to see if I hop in there as well. Again, thanks @DataJim for the suggestions. They/you're on the list of suggestions and suggestors. Let's see how it plays out. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

6 · Reply

Market Cap	155.26M
Revenue (ttm)	0.00
Net Income (ttm)	-11.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	117,911
Avg Vol	211,662
Day's Range	N/A - N/A
Shares Out	127.26M
Stochastic %K	7%
Beta	0.22
Analysts	Strong Sell
Price Target	$8.00